INTRODUCTION
============

In the past decade, low-dose methotrexate (MTX) has become the disease-modifying antirheumatic drug of choice in the treatment of rheumatoid arthritis (RA). Subcutaneously (SC) administered MTX is well absorbed, appears to overcome the problems associated with oral administration, including variable absorption and saturation of the absorption mechanism with increasing doses, and is well tolerated \[[@R1]\]. Recent studies have also confirmed the improved usability and tolerability of subcutaneous application \[[@R2]-[@R4]\], in particular in comparison to intramuscular injection \[[@R2]\]. However, several patients still experience problems to apply several millilitres of liquid MTX every week and report also local side effects associated with the injected volume.

A 6-month, prospective, randomized, double-dummy trial compared the efficacy and safety of SC versus oral administration of MTX in 384 patients with RA \[[@R5]\]. Patients were randomly assigned to receive 15 mg/week of MTX either orally (two 7.5 mg tablets) or SC (prefilled syringe containing 10 mg/ml). After 6 months, significantly more patients treated with SC MTX than with oral MTX showed ACR20 (78% *vs* 70%) and ACR70 (41% *vs* 33%) responses. Patients with disease duration ≥ 12 months had even higher ACR20 response rates (89% for SC administration and 63% for oral). Tolerability did not differ between the two groups.

In a phase I study, 12 healthy male subjects received 15 mg MTX SC either as 50 mg/ml solution or as a 10 mg/ml concentration. Both concentrations were shown to be bioequivalent with regard to AUC (medac, data on file). However, the rate of absorption expressed by C~max~ was different with higher C~max~ concentrations achieved after administration of the higher concentrated solution. For the metabolite 7-hydroxy-MTX, similarity in rate and extent of absorption for SC administration was confirmed. Because of the bioequivalence of AUC of both concentrations, no difference in the efficacy and the safety of the two formulations was expected. Local tolerability was similar in both groups. Only three cases of mild erythema were observed (one with the concentration of 50 mg/ml and two with the concentration of 10 mg/ml). All events occurred immediately after injection and resolved within 2 hours after injection.

The objectives of the subsequent study were the direct comparisons of local tolerability, usability, satisfaction and preference of two MTX solutions with different concentrations after SC administration in a larger number of patients with RA.

STUDY PARTICIPANTS AND METHODS
==============================

Objectives
----------

The primary study objective was to assess the overall preference of RA patients for continuous MTX treatment with either the medium-concentration formulation (MC) (2.0 ml of 10 mg/ml solution; need to apply needle) or the high-concentration formulation (HC) (0.4 ml of 50 mg/ml pre-filled syringe; pre-attached needle) by repeated SC injections.

Secondary objectives included satisfaction, usability and local tolerability assessed by patients, physicians and study nurses.

Study Design
------------

This open, comparative, within-patient controlled, multicentre study enrolled 132 patients at 16 centres in Germany between November 2007 and November 2008. Patient enrolment by centre ranged between 1 and 24 patients. Patients received 20 mg MTX administered SC *via*MC (2 ml of the 10 mg/ml solution) once weekly for 3 weeks followed by HC (0.4 ml of the 50 mg/ml solution) for another three weeks. The physicians or the study nurses performed the first injection of every type of syringe (1^st^ and 4^th^ injection within the study), the following two injections of every type of syringe were performed by the patients themselves (2^nd^, 3^rd^, 5^th^ and 6^th^ injection within the study). Questionnaires and visual analogue scales were used to document satisfaction, usability and local tolerability. Safety laboratory testing (haematology and biochemistry) were performed at baseline, after 3 weeks and at the end of the study.

Patients
--------

The study included patients with a diagnosis of RA according to the ACR criteria \[[@R6]\]. Patients were 18 to 75 years old and had received oral MTX- which is among parenteral application also in accordance with national recommendations for treatment of RA \[[@R7]\] - for at least 6 weeks prior to study start and required an intensified therapy due to remaining RA activity (DAS28 \> 2.6). After study termination every patient received appropriate RA treatment at the discretion of the investigator.

The main exclusion criteria were: prior treatment with parenteral MTX or biologicals; concomitant treatment with another DMARD or a biological; renal insufficiency (serum creatinine \> 1.5 x ULN); liver function test abnormalities (AST or ALT \> 2 x ULN, bilirubin \> 5 mg/dl); impaired haematopoiesis (platelets \< 100 x 10^9^/l, leukocytes \< 3.5 x 10^9^/l), anaemia (haemoglobin \< 10 g/dl); severe acute or chronic infections; malignant disease; alcohol or drug addiction; history of generalised allergic reactions or serious adverse reactions to the study medication or other components of the injection solution; women with child-bearing potential without reliable contraception; men who had a partner with child-bearing potential and did not use a condom or a cervical cap/diaphragm with spermicide during the study and for at least 6 months thereafter; pregnant or breast-feeding women; any other subcutaneously administered drugs (e.g. insulin, heparin); concurrent vaccination with live vaccines.

Previous therapy with other DMARDs and concomitant therapy with nonsteroidal antirheumatic drugs or corticosteroids were permitted during the study: combination therapy with one or more DMARDs or a biological immuno-modulator (e.g. TNF-α blockers); drugs causing folate deficiency (e.g. sulfonamides, trimethoprim-sulfamethoxazole); live-virus vaccinations. Patients were allowed to receive oral folic acid once a week, 24 hours after the MTX dose, with the dose to remain constant throughout the study.

Assessment of Patient-Reported, Physician-Reported and Study Nurse/Physician-Reported Outcomes
----------------------------------------------------------------------------------------------

Table **[1](#T1){ref-type="table"}** summarises questions and answers concerning patient-reported, physician-reported and study nurse/physician-reported outcomes.

Assessment of Safety
--------------------

All patients who received at least one dose of study medication were evaluated for the occurrence of adverse events, serious adverse events and clinical laboratory abnormalities. Severity of adverse events was assessed by the investigator as mild, moderate, severe and life-threatening whereas clinical laboratory values were judged with respect to clinical significance.

Study Medication
----------------

Study drug consisted of the commercially available MTX medium-concentration formulation (10 mg/ml solution; need to apply a needle; metex^®^in Germany, metoject^®^ in other countries, manufacturer: medac Gesellschaft für klinische Spezialpräparate mbH, Hamburg, Germany) and a prefilled syringe MTX high-concentration formulation (50 mg/ml solution; pre-attached needle) (Fig. **[1](#F1){ref-type="fig"}**); both formulations were provided by medac GmbH, Germany.

Statistical Analysis
--------------------

The primary objective, i.e. the proportion of patients deciding in favour of the HC syringe, was subjected to statistical testing by applying a two-sided one-group chi-square test on a significance level of 5%. For sample size estimation, sufficient power for the statistical test was required to detect an increase of the rate of patients deciding to use the HC syringe for future MTX treatment to at least 70%. A one-group chi-square test with a 5% two-sided significance level would have 90% power to detect the difference between the null hypothesis rate of 55% and the alternative rate of 70% with a sample size of 110 patients.

To assess the local tolerability at the site of injection, frequency distributions of mild, moderate and severe signs and symptoms of swelling, itching, erythema, haematoma and pain were presented. Treatment-specific differences between ordinal data were evaluated using Wilcoxon signed-rank tests on an explorative perspective. All other parameters were analysed descriptively using robust measures of location and dispersion such as medians and 1^st^ (Q1) and 3^rd^ quartiles (Q3).

Ethics
------

The study was performed in accordance with the Good Clinical Practice guidelines recommended by the International Conference on Harmonization (ICH) of Technical Requirements. Ethics committees relevant to the respective study sites approved the study protocol. Written informed consent was obtained from all patients.

Funding
-------

The study was supported by medac Gesellschaft für klinische Spezialpräparate mbH, Hamburg, Germany.

RESULTS
=======

Patient Characteristics
-----------------------

Of the 132 patients enrolled, one was excluded from the safety-analysis set (due to missing study visits (1^st^, 2^nd^ and 4^th^ injection) and lack of any source data) and additional 3 were excluded from the full-analysis set (due to injection of merely one type of syringe). Of the 128 patients included in the full-analysis set, 34 were men and 94 women. Median age was 56 years (range: 18 to 75 years), median weight 78 kg (range: 49 to 116 kg) and median body height 165 cm (range: 150 to 188 cm). Median baseline Disease Activity Score of 28 joints (DAS28) was 4.3 (range 2 to 8) and median duration of RA in the patients was 3 years (range: 1 to 39 years). Sixty-three (49.2%) patients had previously received MTX treatment at dosages ranging between 7.5 to 25 mg/week and differed from those dosages given at study start. 85.1% of the patients received MTX dosages of 15 or 20 mg/week (6 patients received more than 20mg oral MTX, 1 patient received 25 mg, the other ones 22.5 mg).

Efficacy
--------

### Patient-Reported Outcomes

The primary efficacy variable was to quantify the decision of the patient for future MTX treatment (50 mg/ml syringe *vs* 10 mg/ml syringe) following repeated SC injections of both formulations. At the end of the study, 93.0% of all patients stated that they would prefer the HC formulation compared to 2.3% of the patients expressing a preference for the MC formulation (95% confidence interval: \[87.1%; 96.7%\]). The result was highly statistically significant (*P*\<0.0001).

At the end of the study, overall assessment of the patients of the HC formulation was "good" and "very good" in 90.6% of the patients compared to 1.6% with a "poor" and "very poor" overall assessment. The patients' overall assessment of the MC formulation was "good" and "very good" in 34.4% of the patients compared to 17.2% with a "poor" and "very poor" overall assessment (Fig. **[2](#F2){ref-type="fig"}**). This advantage in favour of the HC formulation was statistically significant (*P*\<0.0001).

89.1% of the patients assessed the usability of having a pre-attached needle with the small syringe (HC formulation) as an "advantage" and "great advantage" and 3.1% as a "disadvantage" and "great disadvantage".

87.5% of the patients reported that the smaller volume in the HC formulation was more suitable ("agree" and "fully agree") compared to the larger volume with the MC formulation. 1.6% of the patients disagreed in this regard.

Using a visual analogue scale, patient's global assessment of syringe usability was 63.5 mm (Q1-Q3: 49-92) after MC administrations which increased significantly to 95.0 mm (Q1-Q3: 85-99) after administration of the HC formulation (P \< 0.0001).

### Physician-Reported Outcomes

Using a visual analogue scale, physician-reported global assessment of syringe usability was 82.0 mm (Q1-Q3: 59-100) at the time of administration of the MC formulation. A significant increase in to 96.0 mm (Q1-Q3: 86-100) was observed at time of HC administration (*P*\< 0.0001).

### Study Nurse/Physician-Reported Outcomes

All study nurses and physicians assessed the usability of having a pre-attached needle with the small syringe (HC formulation) as an "advantage" or "great advantage".

87.5% found that the smaller volume in the HC formulation was more suitable ("agree" and "fully agree") compared to the larger volume with the MC formulation. 12.5% saw no difference in this regard.

At the end of the study, study nurses' and investigators' overall assessment of the HC formulation was "good" (18.8%) and "very good" (81.2%). The overall assessment of the MC formulation was "good" in 31.3% of cases, "very good" in 12.5% and no preference in 50% (Fig.**[3](#F3){ref-type="fig"}**).

Safety
------

Adverse events were coded according to the Medical Dictionary for Regulatory Affairs (MedDRA). Adverse events were reported in 25 (19.1%) of the 131 patients valid for safety analysis. The number of patients experiencing adverse events was 14 (10.7%) and 15 (11.5%) with MC and HC formulation, respectively (Table **[2](#T2){ref-type="table"}**).

All adverse events expect the one documented within the system organ class "Injury, poising and procedural complications" were judged to be at least possibly drug-related. The most frequent adverse events and drug-related adverse events were gastrointestinal disorders (6.1%), investigations (3.8%) and general disorders and administration site conditions irritations (3.1%). Most adverse events were of mild and moderate intensity. No relevant differences were observed between the two MTX formulations with the exception of five cases of mild and moderate increases in liver enzymes documented within the system organ class investigations occurring during HC treatment compared to no cases during MC treatment.

Three serious adverse events were reported: One occurred during HC-treatment phase two days after the 5^th^ injection (cheek bone fracture) and two others (back pain and left ear mastoiditis) within 28 days after the final examination. All events were considered unrelated to study medication by the investigator.

Three subjects discontinued study participation due to adverse events. These included coughing, dizziness and nausea/sicca symptoms/pain. All events were non-serious and considered as possibly related to study medication.

With regard to overall local tolerability including erythema, swelling, itching, pain and haematoma at the injection site, HC treatment was slightly better tolerated than MC treatment. Physicians' assessment of the injection site showed an absence of erythema with HC treatment in 79.7% of patients compared to 71.1% with MC treatment, which was statistically significant (*P*= 0.0123) and tended to be confirmed by patients' assessment.

For all laboratory categories (haematology and biochemistry), mean parameter changes were minor including those of liver function tests. Except for a mean decrease in CRP by 4 mg/l, mean changes were of no clinical relevance.

DISCUSSION
==========

The results of the study show that repeat dosing of the novel high-concentration (HC) MTX solution available in a prefilled syringe with a pre-attached needle yields a significantly better acceptance by patients and healthcare professionals than the medium-concentration (MC) solution with a syringe to which the needle still has to be attached.

The MTX formulations differ also considerably with regard to usability and overall preference in numerous patients with RA who self-administered the prefilled MTX syringes. At the end of the study 93% of the patients preferred HC over MC as further treatment. Physicians' and patients' global assessments of syringe usability showed also highly statistically significant differences (*P*\< 0.0001) in favour of the HC formulation.

Reasons for this preference also include a smaller volume of administered drug, which improves the comfort of injection and may represent a psychological benefit for the patient. In addition, the pre-attached needle (HC formulation) allows a safer handling in comparison to the MC syringe, for which the needle must first be attached to the syringe body.

A within patient-controlled design was considered the most appropriate approach to determine whether the switch to the newly available HC treatment has the ability to increase patient's satisfaction of subcutaneous MTX treatment compared to the previously available MC treatment. Due to different sizes of syringes blinding of patients and nurses was not feasible within this trial. However, the study results may be biased due to the fact that the treatment sequence was not randomized. But, looking at the huge numerical advantage of HC, this bias can be considered to be negligible with respect to the overall study conclusion.

Differences regarding local tolerability were slightly in favour of HC treatment. Erythema occurred significantly less often with HC treatment compared to MC treatment. Overall patient assessment was confirmed by physician and study nurse assessments who expressed similar preferences and conclusions as the patients. In general, quantity and quality of adverse events did not differ between the two formulations to a relevant extent.

This study focused on safety and tolerability and not on efficacy. However, as the superior efficacy of SC administered MTX has been proven in a recent 6-month, multicenter, randomized, double-blind, controlled trial in comparison to oral MTX in 384 MTX-naïve patients with active RA \[[@R5]\], similar clinical results can be expected for the novel HC formulation. Parenteral MTX treatment is in accordance with current practice guidelines which recommend to consider a switch to the intramuscular or SC route in patients with poor compliance, inadequate effectiveness, or gastrointestinal side effects \[[@R8],[@R9]\]. Taking into account the evidence from other studies which have confirmed the improved usability and tolerability of SC administration of MTX also in comparison to intramuscular injection \[[@R2]-[@R4]\], the newly developed 50 mg/ml prefilled syringe appears to be a highly preferred treatment option for patients with RA in need of MTX. This is supported by the strong appreciation of the patients as well as their attending healthcare professionals for its usability and tolerability.

CONCLUSIONS
===========

A smaller volume of administered drug, the usability of being able to use a pre-attached needle with the small prefilled syringe and an improved local tolerability have contributed to the preference of the HC small syringe to apply subcutaneous MTX in active RA patients. This assessment was supported by similar assessments made by physicians and study nurses. With the exception of erythema which occurred significantly less often with HC treatment quality and quantity of adverse events did in general not differ between the two formulations.
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KEY MESSAGES
============

Patients, physicians and nursing staff prefer a high-concentration prefilled syringe over a medium-concentration syringe for SC administration of MTX.

Superior usability and overall satisfaction contributed to this preference. Local tolerability trended to be advantageous for HC and was partly significant for erythema.

![Comparison of the methotrexate prefilled syringe 10 mg/ml and 50 mg/ml true to scale. MTX=methotrexate.](TORJ-4-15_F1){#F1}

![Patients' overall assessment of methotrexate prefilled syringe 10 mg/ml and 50 mg/ml.](TORJ-4-15_F2){#F2}

![Study nurses' and physicians' overall assessment of methotrexate prefilled syringe 10 mg/ml and 50 mg/ml.](TORJ-4-15_F3){#F3}

###### 

Preference and Usability Outcomes[\*](#T1F1){ref-type="table-fn"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient-Reported Outcomes**
  ** Overall preference (primary endpoint)**
  * "Which of the pre-filled syringes would you prefer from now on?"*
  ** Patient satisfaction**
  * "How would you assess, in summary, the small/large syringe at the end of the study?"*
   Five categories were suggested: "very poor", "poor", "no preference", "good" and "very good".
   **Syringe with or without pre-attached needle**
   *"How do you like the pre-attached needle (small syringe) in comparison to one that still has to be attached (large syringe)?"*
   Five categories were suggested: "great disadvantage", "disadvantage", "no difference", "advantage", and "great advantage".
   **Usability of syringe volume**
   *"Do you feel comfortable with the fact that the injection liquid is five times less in the small syringe than in the large syringe?"*
   Five possible answers were suggested: "fully disagree", "disagree", "indifferent", "agree" and "fully agree".
   **Local tolerability**
   Occurrence of erythema, swelling, itching, pain and haematoma assessed as "none", "mild", "moderate" or "severe".
   **Usability of the 10 mg/ml syringe at the 2^nd^ and 3^rd^ injection (MC formulation) and of the 50 mg/ml syringe at the 5^th^and 6^th^ injection (HC formulation)**
   Rated on a visual scale from 0 (not convenient = 0 mm) to 10 (very convenient = 100 mm).
  **Physician-Reported Outcomes**
   **Usability of the 10 mg/ml syringe at the 1^st^ injection (MC formulation) and of the 50 mg/ml syringe at the 4^th^ injection (HC formulation)**
   Rated on a visual scale from 0 (not convenient = 0 mm) to 10 (very convenient = 100 mm).
   **Local tolerability**
   Occurrence of erythema, swelling, itching, pain and haematoma assessed as "none", "mild", "moderate" or "severe".
  **Study Nurse/Physician-Reported Outcomes**
   **Syringe with or without pre-attached needle**
   *"How do you like the pre-attached needle (small syringe) in comparison to the one which still has to be attached (large syringe)?"*
   Five categories were suggested: "great disadvantage", "disadvantage", "no difference", "advantage", and "great advantage".
   **Usability of syringe volume**
   *"Do you feel comfortable with the fact that the injection liquid is five times less in the small syringe than in the large syringe?"*
   Five possible answers were suggested: "fully disagree", "disagree", "indifferent", "agree" and "fully agree".
   **Overall assessment of the small prefilled syringe**
   Five categories were suggested: "very poor", "poor", "no preference", "good" and "very good".
   **Overall assessment of the large prefilled syringe**
   Five categories were suggested: "very poor", "poor", "no preference", "good" and "very good".
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Original in German.

###### 

Adverse Events

  --------------------------------------------------------------------------------------------------------------------------------
  MedDRA System Organ Class/Preferred Terms                              MTX Medium Concentration\   MTX High\        Total\
                                                                         n=131\                      Concentration\   n=131\
                                                                         n (%)                       n=131\           n (%)
                                                                                                     n (%)            
  ---------------------------------------------------------------------- --------------------------- ---------------- ------------
  Number or patients with adverse events                                 14 (10.7)                   15 (11.5)        25 (19.1)

                                                                                                                      

  Gastrointestinal disorders                                             5 (3.8)                     4 (3.1)          8 (6.1)

   Abdominal pain                                                           0 (0.0)                     2 (1.5)          2 (1.5)

   Abdominal pain upper                                                     0 (0.0)                     1 (0.8)          1 (0.8)

   Diarrhoea                                                                2 (1.5)                     0 (0.0)          2 (1.5)

   Mouth ulceration                                                         1 (0.8)                     0 (0.0)          1 (0.8)

   Nausea                                                                   3 (2.3)                     1 (0.8)          4 (3.1)

                                                                                                                      

  Investigations                                                         0 (0.0)                     5 (3.8)          5 (3.8)

   Alanine aminotransferase increased                                       0 (0.0)                     5 (3.8)          5 (3.8)

   Aspartate aminotransferase increased                                     0 (0.0)                     2 (1.5)          2 (1.5)

   Gamma-glutamyltransferase increased                                      0 (0.0)                     1 (0.8)          1 (0.8)

   White blood cell count decreased                                         0 (0.0)                     1 (0.8)          0 (0.0)

                                                                                                                      

  General disorders and administration site conditions                   3 (2.3)                     2 (1.5)          4 (3.1)

   Fatigue                                                                  1 (0.8)                     0 (0.0)          1 (0.8)

   Feeling abnormal                                                         1 (0.8)                     0 (0.0)          1 (0.8)

   Injection site irritation                                                1 (0.8)                     1 (0.8)          1 (0.8)

   Mucosal dryness                                                          0 (0.0)                     1 (0.8)          1 (0.8)

   Pain                                                                     0 (0.0)                     1 (0.8)          1 (0.8)

                                                                                                                      

  Skin and subcutaneous tissue disorders                                 2 (1.5)                     1 (0.8)          3 (2.3)

   Alopecia                                                                 2 (1.5)                     0 (0.0)          2 (1.5)

   Erythema                                                                 0 (0.0)                     1 (0.8)          1 (0.8)

                                                                                                                      

  Musculoskeletal and connective tissue disorders                        1 (0.8)                     2 (1.5)          2 (1.5)

   Musculoskeletal pain                                                     0 (0.0)                     1 (0.8)          1 (0.8)

   Myalgia                                                                  0 (0.0)                     1 (0.8)          1 (0.8)

   Pain in extremity                                                        0 (0.0)                     1 (0.8)          1 (0.8)

   Rheumatoid arthritis (worsening)                                         1 (0.8)                     0 (0.0)          1 (0.8)

                                                                                                                      

  Nervous system disorders                                               1 (0.8)                     1 (0.8)          2 (1.5)

   Cervical root pain                                                       0 (0.0)                     1 (0.8)          1 (0.8)

   Dizziness                                                              1 (0.8)                     0 (0.0)          1 (0.8)

                                                                                                                      

  Respiratory, thoracic and mediastinal disorders/ Cough                 2 (1.5)                     0 (0.0)          2 (1.5)

                                                                                                                      

  Infections and infestations/Oral herpes                                1 (0.8)                     0 (0.0)          1 (0.8)

                                                                                                                      

  Ear and labyrinth disorders/Vertigo                                    0 (0.0)                     1 (0.8)          1 (0.8)

                                                                                                                      

  Injury, poisoning and procedural complications/Facial bones fracture   1 (0.8)                     0 (0.0)          1 (0.8)

                                                                                                                      

  Metabolism and nutrition disorders/Anorexia                            1 (0.8)                     0 (0.0)          1 (0.8)

                                                                                                                      

  Vascular disorders Extremity necrosis                                  1 (0.8)                     0 (0.0)          1 (0.8)
  --------------------------------------------------------------------------------------------------------------------------------
